Related Experiment Video

Updated: Aug 24, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Carvedilol: beta-blockade and beyond

Alice F Stroe1, Mihai Gheorghiade

  • 1Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

Reviews in Cardiovascular Medicine
|June 9, 2004
PubMed

Insights

Carvedilol, a beta- and alpha-1 blocker, offers significant benefits for heart failure and post-myocardial infarction patients. Its unique properties also aid in managing comorbid conditions common in heart failure.

Area of Science:

  • Pharmacology and Cardiovascular Medicine
  • Adrenergic Receptor Antagonism

Background:

  • Heart failure (HF) management requires addressing complex comorbidities.
  • Carvedilol is an adrenergic antagonist with dual beta- and alpha-1 blocking properties.
  • Existing research indicates carvedilol's clinical utility in HF and post-myocardial infarction settings.

Purpose of the Study:

  • To review the clinical benefits of carvedilol in heart failure management.
  • To explore the role of carvedilol's ancillary properties in clinical trial outcomes.
  • To assess carvedilol's advantages in treating comorbid conditions associated with heart failure.

Main Methods:

  • Review of clinical trials and pharmacological data.
  • Analysis of carvedilol's receptor binding profile (nonselective beta- and alpha-1 blockade).
  • Evaluation of carvedilol's efficacy in patients with comorbid cardiovascular and metabolic diseases.

Main Results:

  • Carvedilol demonstrates significant clinical benefit in heart failure and post-myocardial infarction patients.
  • Unique ancillary properties of carvedilol contribute to positive clinical trial results.
  • Carvedilol shows particular advantages in treating comorbidities like coronary artery disease, hypertension, diabetes, and atrial fibrillation.

Conclusions:

  • Carvedilol is a valuable therapeutic agent for heart failure patients.
  • Its multifaceted action, including receptor blockade and ancillary properties, supports its use.
  • Carvedilol effectively manages common comorbidities that exacerbate heart failure progression.

Related Concept Videos

Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...